HSA Approves Two H1N1 Influenza Vaccines
3 November 2009
The Health Sciences Authority (HSA) has approved the following two H1N1 influenza vaccines on 9 and 15 Oct 2009 respectively:
i] Panvax H1N1 Vaccine by CSL Limited, Australia
ii] Pandemrix H1N1 Injection by Glaxo Smithkline Biologicals
Panvax® and Pandemrix® contain the A/California/7/2009 (H1N1) viral antigen and are able to induce an adequate immune response. Both vaccines were assessed to have met the criteria for quality, safety and efficacy for the use by adults above 18 years against the current circulating influenza A(H1N1) virus in a pandemic situation.
These vaccines will be distributed by the Ministry of Health to local doctors and clinics, and should be used in accordance with the official guidance.
As more data becomes available for these two vaccines, the product labeling will be reviewed and updated where necessary. The latest approved Singapore product labeling can be accessed here.